Futura Medical (AIM:FUM), the consumer healthcare group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that pursuant to the completion of the recent fundraise, the Directors of the Company subscribed for 23,500,000 Subscription Shares.
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
| a) | Name | Alexander Duggan |
| 2 | Reason for the notification |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Futura Medical plc |
| b) | LEI | 21380053QLT46UNV2303 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares at 0.2p each GB0033278473 |
| b) | Nature of the transaction | Purchase of ordinary shares |
| c) | Price(s) and volume(s) | | Price | Volume |
|---|
| 0.2p | 12,500,000 |
|
| d) | Aggregated information - Aggregated volume - Price | 12,500,000 £25,000 |
| e) | Date of the transaction | 25 September 2026 |
| f) | Place of the transaction | London Stock Exchange |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
| a) | Name | Andrew Unitt |
| 2 | Reason for the notification |
| a) | Position/status | Non-Executive Chairman |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Futura Medical plc |
| b) | LEI | 21380053QLT46UNV2303 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares at 0.2p each GB0033278473 |
| b) | Nature of the transaction | Purchase of ordinary shares |
| c) | Price(s) and volume(s) | |
| d) | Aggregated information - Aggregated volume - Price | 6,000,000 £12,000 |
| e) | Date of the transaction | 25 September 2026 |
| f) | Place of the transaction | London Stock Exchange |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
| a) | Name | Roy Davis |
| 2 | Reason for the notification |
| a) | Position/status | Non-Executive Director |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Futura Medical plc |
| b) | LEI | 21380053QLT46UNV2303 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares at 0.2p each GB0033278473 |
| b) | Nature of the transaction | Purchase of ordinary shares |
| c) | Price(s) and volume(s) | |
| d) | Aggregated information - Aggregated volume - Price | 2,500,000 £5,000 |
| e) | Date of the transaction | 25 September 2026 |
| f) | Place of the transaction | London Stock Exchange |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
| a) | Name | Ken James |
| 2 | Reason for the notification |
| a) | Position/status | Executive Director and Head of R&D |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Futura Medical plc |
| b) | LEI | 21380053QLT46UNV2303 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares at 0.2p each GB0033278473 |
| b) | Nature of the transaction | Purchase of ordinary shares |
| c) | Price(s) and volume(s) | |
| d) | Aggregated information - Aggregated volume - Price | 2,500,000 £5,000 |
| e) | Date of the transaction | 25 September 2026 |
| f) | Place of the transaction | London Stock Exchange |